Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) Return on Capital Employed (2016 - 2025)

China Pharma Holdings filings provide 15 years of Return on Capital Employed readings, the most recent being 20.24% for Q4 2025.

  • On a quarterly basis, Return on Capital Employed rose 2986.0% to 20.24% in Q4 2025 year-over-year; TTM through Dec 2025 was 20.24%, a 2986.0% increase, with the full-year FY2025 number at 20.84%, up 2220.0% from a year prior.
  • Return on Capital Employed hit 20.24% in Q4 2025 for China Pharma Holdings, up from 39.63% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 1.9% in Q3 2023 to a low of 50.1% in Q4 2024.
  • Median Return on Capital Employed over the past 5 years was 18.55% (2021), compared with a mean of 20.09%.
  • Biggest five-year swings in Return on Capital Employed: soared 4013bps in 2021 and later plummeted -4163bps in 2024.
  • China Pharma Holdings' Return on Capital Employed stood at 8.58% in 2021, then plummeted by -167bps to 22.89% in 2022, then soared by 63bps to 8.47% in 2023, then plummeted by -492bps to 50.1% in 2024, then soared by 60bps to 20.24% in 2025.
  • The last three reported values for Return on Capital Employed were 20.24% (Q4 2025), 39.63% (Q3 2025), and 42.24% (Q2 2025) per Business Quant data.